Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Short-term Investments (2021 - 2025)

InMed Pharmaceuticals' Short-term Investments history spans 5 years, with the latest figure at $42675.0 for Q4 2025.

  • For Q4 2025, Short-term Investments rose 4.63% year-over-year to $42675.0; the TTM value through Dec 2025 reached $42675.0, up 4.63%, while the annual FY2025 figure was $43384.0, 0.74% up from the prior year.
  • Short-term Investments reached $42675.0 in Q4 2025 per INM's latest filing, roughly flat from $42859.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $46098.0 in Q1 2022 to a low of $40582.0 in Q1 2025.
  • Average Short-term Investments over 5 years is $43393.8, with a median of $43074.5 recorded in 2024.
  • Peak YoY movement for Short-term Investments: dropped 8.27% in 2024, then rose 4.63% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $45356.0 in 2021, then dropped by 5.08% to $43053.0 in 2022, then increased by 3.27% to $44462.0 in 2023, then decreased by 8.27% to $40787.0 in 2024, then grew by 4.63% to $42675.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Short-term Investments are $42675.0 (Q4 2025), $42859.0 (Q3 2025), and $43384.0 (Q2 2025).